Journal of Microbiology

The Microbiological Society of Korea (한국미생물학회)
권호 표지

Guided Selection of Human Antibody Light Chains against TAG-72 Using a Phage Display Chain Shuffling Approach

  • Kim, Sang-Jick (Therapeutic Antibody Research Center, Korea Research Institute of Bioscience and Biotechnology) ;
  • Hong, Hyo-Jeong (Therapeutic Antibody Research Center, Korea Research Institute of Bioscience and Biotechnology)
  • Published : 2007.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

To enhance therapeutic potential of murine monoclonal antibody, humanization by CDR grafting is usually used to reduce immunogenic mouse residues. Most humanized antibodies still have mouse residues critical for antigen binding, but the mouse residues may evoke immune responses in humans. Previously, we constructed a new humanized version (AKA) of mouse CC49 antibody specific for tumor-associated glycoprotein, TAG-72. In this study, to select a completely human antibody light chain against TAG-72, guided selection strategy using phage display was used. The heavy chain variable region (VH) of AKA was used to guide the selection of a human TAG-72-specific light chain variable region (VL) from a human VL repertoire constructed from human PBL. Most of the selected VLs were identified to be originated from the members of the human germline VK1 family, whereas the VL of AKA is more homologous to the VK4 family. Competition binding assay of the selected Fabs with mouse CC49 suggested that the epitopes of the Fabs overlap with that of CC49. In addition, they showed better antigen-binding affinity compared to parental AKA. The selected human VLs may be used to guide the selection of human VHs to get completely human anti-TAG72 antibody.

Keywords

References

  1. Beiboer, S.H., A. Reurs, R.C. Roovers, J.W. Arends, N.R. Whitelegg, A.R. Rees, and H.R. Hoogenboom. 2000. Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent. J. Mol. Biol. 296, 833-849 https://doi.org/10.1006/jmbi.2000.3512
  2. Burton, D.R., C.F. Barbas, 3rd, M.A. Persson, S. Koenig, R.M. Chanock, and R.A. Lerner. 1991. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. USA 88, 10134-10137
  3. De Pascalis, R., N.R. Gonzales, E.A. Padlan, P. Schuck, S.K. Batra, J. Schlom, and S.V. Kashmiri. 2003. In vitro affinity maturation of a specificity-determining region-grafted humanized anticarcinoma antibody: isolation and characterization of minimally immunogenic high-affinity variants. Clin. Cancer Res. 9, 5521-5531
  4. Divgi, C.R., A.M. Scott, L. Dantis, P. Capitelli, K. Siler, S. Hilton, R.D. Finn, N. Kemeny, D. Kelsen, L. Kostakoglu, J. Schlom, and S.M. Larson. 1995a. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma. J. Nucl. Med. 36, 586-592
  5. Divgi, C.R., A.M. Scott, S. Gulec, E.K. Broussard, N. Levy, C. Young, P. Capitelli, F. Daghighian, J.M. Williams, and R.D. Finn. 1995b. Pilot radioimmunotherapy trial with 131I-labeled murine monoclonal antibody CC49 and deoxyspergualin in metastatic colon carcinoma. Clin. Cancer Res. 1, 1503-1510
  6. Divgi, C.R., A.M. Scott, K. McDermott, P.S. Fallone, S. Hilton, K. Siler, N. Carmichael, F. Daghighian, R.D. Finn, A.M. Cohen, J. Schlom, and S.M. Larson. 1994. Clinical comparison of radiolocalization of two monoclonal antibodies (mAbs) against the TAG-72 antigen. Nucl. Med. Biol. 21, 9-15 https://doi.org/10.1016/0969-8051(94)90124-4
  7. Figini, M., J.D. Marks, G. Winter, and A.D. Griffiths. 1994. In vitro assembly of repertoires of antibody chains on the surface of phage by renaturation. J. Mol. Biol. 239, 68-78 https://doi.org/10.1006/jmbi.1994.1351
  8. Figini, M., L. Obici, D. Mezzanzanica, A. Griffiths, M.I. Colnaghi, G. Winter, and S. Canevari. 1998. Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection. Cancer Res. 58, 991-996
  9. Gonzales, N.R., E.A. Padlan, R. De Pascalis, P. Schuck, J. Schlom, and S.V. Kashmiri. 2003. Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues. Mol. Immunol. 40, 337-349 https://doi.org/10.1016/S0161-5890(03)00166-4
  10. Iwahashi, M., D.E. Milenic, E.A. Padlan, R. Bei, J. Schlom, and S.V. Kashmiri. 1999. CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity. Mol. Immunol. 36, 1079-1091 https://doi.org/10.1016/S0161-5890(99)00094-2
  11. Jespers, L.S., A. Roberts, S.M. Mahler, G. Winter, and H.R. Hoogenboom. 1994. Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. Bio/Technol. 12, 899-903 https://doi.org/10.1038/nbt0994-899
  12. Kashmiri, S.V., L. Shu, E.A. Padlan, D.E. Milenic, J. Schlom, and P.H. Hand. 1995. Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49. Hybridoma 14, 461-473 https://doi.org/10.1089/hyb.1995.14.461
  13. Kim, S.J., M.H. Jang, J.T. Stapleton, S.O. Yoon, K.S. Kim, E.S. Jeon, and H.J. Hong. 2004. Neutralizing human monoclonal antibodies to hepatitis A virus recovered by phage display. Virology 318, 598-607 https://doi.org/10.1016/j.virol.2003.10.014
  14. Marks, J.D., H.R. Hoogenboom, T.P. Bonnert, J. McCafferty, A.D. Griffiths, and G. Winter. 1991. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222, 581-597 https://doi.org/10.1016/0022-2836(91)90498-U
  15. Mulligan, T., J.A. Carrasquillo, Y. Chung, D.E. Milenic, J. Schlom, I. Feuerstein, C. Paik, P. Perentesis, J. Reynolds, and G. Curt. 1995. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Clin. Cancer Res. 1, 1447-1454
  16. Pavlinkova, G., D. Colcher, B.J. Booth, A. Goel, and S.K. Batra. 2000. Pharmacokinetics and biodistribution of a light-chainshuffled CC49 single-chain Fv antibody construct. Cancer Immunol. Immunother. 49, 267-275 https://doi.org/10.1007/s002620000108
  17. Persson, M.A., R.H. Caothien, and D.R. Burton. 1991. Generation of diverse high-affinity human monoclonal antibodies by repertoire cloning. Proc. Natl. Acad. Sci. USA 88, 2432-2436
  18. Tamura, M., D.E. Milenic, M. Iwahashi, E. Padlan, J. Schlom, and S.V. Kashmiri. 2000. Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only. J. Immunol. 164, 1432-1441 https://doi.org/10.4049/jimmunol.164.3.1432
  19. Thor, A., R. Muraro, F. Gorstein, N. Ohuchi, M. Viglione, C.A. Szpak, W.W. Johnston, and J. Schlom. 1987. Adjunct to the diagnostic distinction between adenocarcinomas of the ovary and the colon utilizing a monoclonal antibody (COL-4) with restricted carcinoembryonic antigen reactivity. Cancer Res. 47, 505-512
  20. Thor, A., N. Ohuchi, C.A. Szpak, W.W. Johnston, and J. Schlom. 1986. Distribution of oncofetal antigen tumor-associated glycoprotein- 72 defined by monoclonal antibody B72.3. Cancer Res. 46, 3118-3124
  21. Watzka, H., K. Pfizenmaier, and D. Moosmayer. 1998. Guided selection of antibody fragments specific for human interferon gamma receptor 1 from a human VH- and VL-gene repertoire. Immunotechnology 3, 279-291 https://doi.org/10.1016/S1380-2933(97)10008-2
  22. Yoon, S.O., T.S. Lee, S.J. Kim, M.H. Jang, Y.J. Kang, J.H. Park, K.S. Kim, H.S. Lee, C.J. Ryu, N.R. Gonzales, S.V. Kashmiri, S.M. Lim, C.W. Choi, and H.J. Hong. 2006. Construction, affinity maturation, and biological characterization of an anti-tumor-associated glycoprotein-72 humanized antibody. J. Biol. Chem. 281, 6985-6992 https://doi.org/10.1074/jbc.M511165200